Merck, 1269105-2.73MG, Exenatide

General description

Exenatide is a 39-amino acid peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor, originally derived from Heloderma suspectum venom. It enhances glucose-dependent insulin secretion and is used in type 2 diabetes management. The USP standard is employed in identity testing, potency assays, and impurity profiling in GLP-1 analog formulations.

The USP biologics peptides category encompasses a diverse range of therapeutic peptides that are essential in managing various medical conditions. These peptides, typically consisting of amino acid sequences of 40 residues or less, are critical for the development of high-quality medicines. The USP provides comprehensive standards, reference materials, and analytical procedures to ensure the identity, quality, purity, and consistency of peptide therapeutics throughout their lifecycle.

The United States Pharmacopeia (USP) provides quality standards for biologics to ensure their safety, efficacy, and quality throughout the manufacturing process. These standards assist manufacturers in adhering to regulatory requirements and help safeguard public health by reducing risks associated with biologics.

Application
Exenatide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

• Exenatide Injection

Other Notes
Sales restrictions may apply.
This product is intended for use as a reference standard in pharmaceutical research and development. This product is for test and assay use only. It is not tested for animal or human consumption, clinical testing, or therapeutic use.
This product is part of the USP Biologics program.